An interventional study of Ischemic Preconditioning in Traumatic Amputation of Lower Extremity, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Amputation, Traumatic with a site in United States — 12 open to participants now, 15 under way, 1 of them phase 3. Amputation, Traumatic · United States.
Among the 64 studies in Amputation, Traumatic with a site in United States, this one is the 12th largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2024, is one of 47 with no phase, reaches primary completion later than 5 of the 14 other live ones, and was the 55th registered.
112 studies on the registry are indexed under Amputation, Traumatic; 24 are open to participants now.
Browse Amputation, Traumatic studies →12 of the 64 studies in Amputation, Traumatic with a site in United States are open now. Recruiting first, the newest first:
Boninger, Michael, MD · Sites in United States
Ages 22–70
Liberating Technologies, Inc. · Sites in United States
Ages 18+
Walter Reed National Military Medical Center · Sites in United States
Ages 22–65
AtriCure, Inc. · Sites in United States
Ages 18+
Shirley Ryan AbilityLab · Sites in United States
Ages 18–95
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Amputation, Traumatic studies recruiting now, 6 (33%) set no upper age limit and 9 (50%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 1 · Phase 4 1
First in 1996; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is above the median of 15 across 75 interventional studies indexed under Amputation, Traumatic.
Median enrollment 12 across the 53 interventional studies, 60 across the 11 observational. Of the 45 that completed or were terminated, 20 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 64 have an industry lead sponsor. The 10 most frequent:
University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
University of Illinois at Chicago has 1 study filed under Amputation, Traumatic — fewer than ten, so there is no comparison to draw.
2 of the studies in Amputation, Traumatic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07135947Point DesignsTo Evaluate the Clinical Impact of the Point Powered System | 2027-04-01 |
| NCT05929508University of Illinois at ChicagoImproving Mobility and Function Following Transfemoral Amputation: A Novel Approach to Reverse Volumetric Muscle Loss | 2027-06-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 64 studies in Amputation, Traumatic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the relationship between thigh strength and walking ability and assess if using a blood pressure cuff on the leg improves strength and walking performance.
One in every 190 Americans is currently living with the loss of a limb. Following lower limb amputation (LLA), individuals have double the risk of knee and hip pain, a high prevalence of osteoarthritis in the intact limb with a prevalence ratio of 3.3 compared to those without amputation, and up to 90% experience severe back pain. The long-term consequences of LLA may be mitigated through regular use of prosthesis and physical activity, which would also increase the likelihood of returning to work and reintegration of Service Members (SMs) and younger Veterans.
Clinicians and researchers often focus on the prosthetic fit to improve outcomes, however just providing a prosthetic, even the most advanced prosthetic, is not enough to restore function. Interventions targeting physical capabilities to complement device intervention may be key to improving outcomes in individuals with LLA.
Along with increased orthopaedic risks, individuals with traumatic LLA also have an increased risk of cardiovascular events compared to the general population. SMs with traumatic unilateral transfemoral amputation have a 1.58 times greater risk of death from cardiovascular causes and their relative risk of aortic aneurysm is 5.1 times greater than Veterans without amputation. There is evidence to suggest that individuals with LLA have increased peripheral vascular resistance following amputation, leading to vasoconstriction and increased blood pressure. Reduced arterial function (i.e. increased arterial stiffness) is an important measure in those with LLA because it predicts mortality, heart failure, and cardiovascular events. In addition, improved arterial function improves perfusion to muscle and reduces fatigue during exertion. Therefore, strategies that reduce arterial stiffness and vascular resistance in individuals with LLA are important to improve mortality and quality of life for SMs and Veterans.
Therefore, we propose implementing ischemic preconditioning (IC) as a novel intervention to strengthen and hypertrophy leg muscles and increase arterial function for improving outcomes after amputation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this arm, the participant will receive ischemic preconditioning (a blood pressure cuff on the intact limb) inflated to 225mmHg for 5 minutes followed by 5 minutes of reperfusion on a cycle for a total of 50 minutes. This will be completed every other day for 7 session (14 days).
Other: Ischemic Preconditioning
In this arm, the participant will receive ischemic preconditioning (a blood pressure cuff on the intact limb) inflated to 25mmHg for 5 minutes followed by 5 minutes of reperfusion on a cycle for a total of 50 minutes. This will be completed every other day for 7 session (14 days).
Other: Ischemic Preconditioning
A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).
Strength
Comparing leg strength before and after intervention
Time frame: through study completion, an average of 6 weeks
Gait
Comparing leg strength before and after intervention
Time frame: through study completion, an average of 6 weeks
Metabolics
Comparing leg strength before and after intervention
Time frame: through study completion, an average of 6 weeks
Daily Steps/Activity
Comparing leg strength before and after intervention
Time frame: through study completion, an average of 6 weeks
Arterial Stiffness
Comparing leg strength before and after intervention
Time frame: through study completion, an average of 6 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Jun 2027, 38 months after the start.
Of 38 non-industry interventional studies with no phase under Amputation, Traumatic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 58. This study's planned 38 months is above that.
Counting every sponsor, half of 46 studies reached it within 27 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois at Chicago →